Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker
New England Journal of Medicine2006Vol. 354(16), pp. 1685–1697
Citations Over TimeTop 1% of 2006 papers
Stevo Julius, Shawna D. Nesbitt, Brent M. Egan, Michael A. Weber, Eric L. Michelson, Niko Kaciroti, Henry R. Black, Richard H. Grimm, Franz H. Messerli, Suzanne Oparil, M. Anthony Schork
Abstract
Over a period of four years, stage 1 hypertension developed in nearly two thirds of patients with untreated prehypertension (the placebo group). Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension during the study period. Thus, treatment of prehypertension appears to be feasible. (ClinicalTrials.gov number, NCT00227318.).
Related Papers
- → Angiotensin-(1–7) binding at angiotensin II receptors in the rat brain(1995)73 cited
- → Angiotensin receptors in vascular tissue(1976)106 cited
- → Quantification and localisation of angiotensin II receptors and angiotensin converting enzyme in the developing rat heart(1995)27 cited
- → Effect of endotoxin on the angiotensin II receptor in cultured vascular smooth muscle cells(1995)18 cited
- → Characterization of angiotensin II (AII) receptors in rat aortic smooth muscle cells(1990)1 cited